Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1698079

registered interest
date	22/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the guidance entitled 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, published on 20 November 2023, what steps her Department is taking to apply the provisions of section 6.26 on exceptional circumstances.
tabling member constituency	Wythenshawe and Sale East
tabling member printed	Mike Kane
uin	20061
answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>In the vast majority of instances, payments required under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth will be affordable for companies, or can be mitigated by standard price increase processes. In exceptional circumstances only, the scheme allows companies to apply to increase their National Health Service list price, and for older medicines to reduce their top-up payment percentage, even when their wider portfolio is otherwise profitable. To qualify, a product must be demonstrably uneconomic to supply, there must be clear evidence that supply disruption would otherwise occur, and this disruption must have a negative impact on patients or the NHS. The Department already has processes and committees to consider applications for exceptional circumstances, established under previous pricing schemes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20062 question first answered 15/04/2024 08:11:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4316 label Biography information for Mike Kane

1698080

registered interest
date	22/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to section 6.26 of the guidance entitled 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, published on 20 November 2023, whether her Department has been allocated additional resources to consider exceptional circumstances.
tabling member constituency	Wythenshawe and Sale East
tabling member printed	Mike Kane
uin	20062
answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>In the vast majority of instances, payments required under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth will be affordable for companies, or can be mitigated by standard price increase processes. In exceptional circumstances only, the scheme allows companies to apply to increase their National Health Service list price, and for older medicines to reduce their top-up payment percentage, even when their wider portfolio is otherwise profitable. To qualify, a product must be demonstrably uneconomic to supply, there must be clear evidence that supply disruption would otherwise occur, and this disruption must have a negative impact on patients or the NHS. The Department already has processes and committees to consider applications for exceptional circumstances, established under previous pricing schemes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20061 question first answered 15/04/2024 08:11:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4316 label Biography information for Mike Kane

1698101

registered interest
date	22/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Respiratory Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 December 2023 to Question 4959 on Respiratory Diseases: Health Services, how many Acute Respiratory Infection hubs were operating in winter 2023/24.
tabling member constituency	Sheffield Central
tabling member printed	Paul Blomfield
uin	20039
answer	answer is ministerial correction date of answer 03/04/2024 answer text <p>During winter 2022/23, 363 Acute Respiratory Infection (ARI) hubs were implemented by integrated care systems (ICSs). The Department does not hold recorded information on the number of ARI hubs in 2023/24, as this information is held instead by local health bodies. The ambition in the recovery plan for urgent and emergency care is that each local area that would benefit from an ARI hub, has one in place ahead of winter. Evaluations from NHS England suggest that ARI hubs may save general practitioner appointments and accident and emergency attendances.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 03/04/2024 11:27:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4058 label Biography information for Paul Blomfield

1698103

registered interest
date	22/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Surgery: Wellingborough
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce waiting time for elective surgeries for people in Wellingborough constituency.
tabling member constituency	Wellingborough
tabling member printed	Gen Kitchen
uin	20125
answer	answer is ministerial correction date of answer 28/03/2024 answer text <p>Cutting waiting lists is one of the Prime Minister’s top priorities. To reduce the National Health Service’s waitlist, the Department plans to spend more than £8 billion from 2022/23 to 2024/25. This funding will expand capacity by creating a new network of community diagnostic centres, and maximising all available independent sector capacity. In addition, we are managing demand through specialised advice in primary care, and giving patients more control over where they receive their care.</p><p>To reduce waiting times for elective surgeries specifically, we are transforming the way the NHS provides elective surgeries, by increasing activity through dedicated and protected surgical hubs. £1.5 billion of funding has been awarded for the development of new surgical hubs and the expansion of surgical hub sites, as well as increased bed capacity and equipment, to help elective services recover. The hubs will focus on providing high volume low complexity surgery, as recommended by the Royal College of Surgeons of England. There are currently 100 elective surgical hubs that are operational across England, as of March 2024. These surgical hubs help to separate elective care facilities from urgent and emergency care.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 28/03/2024 13:30:06 answering member 4044 label Biography information for Andrew Stephenson
tabling member	5011 label Biography information for Gen Kitchen

1698124

registered interest
date	22/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Obesity: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress NHS England has made on integrating Wegovy to existing weight management structures within primary care settings.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	20056
answer	answer is ministerial correction date of answer 28/03/2024 answer text <p>The National Institute for Health and Care Excellence’s guidance on semaglutide, the active ingredient in wegovy, for managing overweight and obesity was published in March 2023, and updated in September 2023. It recommends semaglutide as a treatment option for patients that meet specified eligibility criteria, and recommends that the treatment is provided within specialist weight management services. These services are typically provided in secondary rather than primary care settings. The Government is committed to the safe introduction of new weight loss drugs into the National Health Service, and is exploring ways to increase access to more people, who meet the relevant eligibility criteria.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 28/03/2024 13:23:44 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4126 label Biography information for Mary Glindon